Navigation Links
Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings
Date:10/12/2009

KENILWORTH, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) is scheduled to announce its sales and earnings results for the 2009 third quarter on Thursday, Oct. 22, 2009.

At approximately 7:15 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2009 third quarter. Fred Hassan, Schering-Plough's chairman and CEO, and other members of management will host the conference call.

To listen live to the call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID # 33373738. A replay of the call will be available beginning later on Oct. 22 through 5 p.m. on Thursday, Oct. 29. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #33373738. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on October 22 through 5 p.m. on November 2.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SO
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
2. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
3. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
4. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
5. Schering-Plough Announces Results of the Early ACS Trial
6. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
10. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Sigmoidoscopes ... new report, "EU5 Sigmoidoscopes Market Outlook to 2020", ... market. The report provides value, in millions of ... (in US dollars) within market segments - Flexible ... and Flexible Non-Video (Fibre) Sigmoidoscopes). The ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre de 2014 ... adelante, Daiichi Sankyo) (TSE: 4568) y Ambit Biosciences (NASDAQ: ... que han llegado a un acuerdo de fusión definitivo ... acciones ordinarias de Ambit Biosciences a un precio de ... una oferta de licitación seguida de una fusión con ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... now offering gum depigmentation treatments for dark gums. Dark ... can make people feel extremely self-conscious about their smiles. ... or dark gums. “I am one of the few ... and I have treated celebrities, business leaders, high-ranking officials ...
(Date:9/30/2014)... In books and movies, plots involving older men chasing ... suggests that the stereotype may be grounded in fact. ... than 12,000 people from Finland. The researchers, led by ... women typically preferred men who were the same age or ... On the other hand, men tended to have a lifelong ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- For millions of ... excess weight and the threat of type 2 diabetes. ... may be tougher for some than for others, depending ... good health, it may not be as effective for ... 2 diabetes," said one expert, Dr. Ruth Loos, director ...
(Date:9/30/2014)... University of Michigan have described a new approach to ... the time needed for more traditional methods. , ... that is undergoing further investigation as a potential treatment ... , In research published online in the Proceedings ... the lab of Stephen Weiss at the U-M Life ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2
... men has increased by 12% in six years, according to the ... diagnosed with the disease, 3,000 of those are men.// ... that they tend to occur more commonly on the back, whereas ... noticeable. Up to 77% of cases are caused by exposure to ...
... a mother's risk of having a hyperactive child. A ... the last three months of pregnancy had children with ... Glover, of Imperial College, London, told that this only ... frequently feeling scared.According to a survey antenatal anxiety ...
... somebody is likely to have an epileptic seizure. ,In ... warning and can lead to ,disability or even death. ... believe ,it may be possible to predict the onset ... ,An ECG records electrical activity from different parts of ...
... years. And while most of the popular remedies used in ... has increased. This powerful pill will //reduce pain, fever, inflammation, ... attacks and stroke. ,In the more than 35 ... few drugs have been developed that can even be compared ...
... one day have the option of having one blast ... up to 25 sessions afterwards, researchers said. //They believe ... for women and may improve the treatment of breast ... the developing world. ,Dr. Emiel Rutgers, of the ...
... new compounds developed for preventing and treating the flue ... only one dose to be effective.// The compounds, known ... flu drug relenza, or zanamivir, which the U.S. Food ... A and B. ,Researchers reported at the International ...
Cached Medicine News:
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
... transducer is a curved ... the higher frequencies. Featuring ... this transducer provides exceptional ... frequency abdominal kidney bladder ...
Medicine Products: